Core Viewpoint - Bid Pharma (688073) is implementing foreign exchange hedging to mitigate currency fluctuation risks due to its import and export business primarily settled in foreign currencies [1] Group 1: Stock Performance - As of October 15, 2025, Bid Pharma's stock closed at 68.47 CNY, up 3.66% from the previous trading day, with a total market capitalization of 6.223 billion CNY [1] - The stock opened at 66.05 CNY, reached a high of 68.64 CNY, and a low of 65.21 CNY, with a trading volume of 50.0698 million CNY and a turnover rate of 1.71% [1] Group 2: Foreign Exchange Hedging Business - The company plans to conduct foreign exchange hedging with a maximum contract value of 600 million CNY on any trading day, and the margin and premium will not exceed 20 million CNY [1] - The hedging transactions will involve currencies such as USD, EUR, GBP, and HKD, utilizing methods including spot foreign exchange, forward foreign exchange, swaps, and options [1] - The board of directors has authorized the chairman or designated personnel to sign relevant documents within the approved limits, effective for 12 months from the board's approval [1] - The company has established a foreign exchange risk management system and implemented multiple risk control measures [1] - The matter has been approved by the 25th meeting of the second board of directors and does not require submission to the shareholders' meeting for approval [1] - The sponsor institution, Guotai Junan Securities, has no objections to the company's foreign exchange hedging business [1]

证券代码：688073 证券简称：毕得医药 公告编号：2025-083 上海毕得医药科技股份有限公司 关于使用部分暂时闲置募集资金进行现金管理的 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 万元 20,000 | | --- | --- | | 投资种类 | 安全性高、流动性好、满足保本要求的投资产品（包 | | | 括但不限于协定性存款、结构性存款、定期存款、大 | | | 额存单等产品） | | 资金来源 | 募集资金 | 已履行及拟履行的审议程序 上海毕得医药科技股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日召开第二届董事会第二十五次会议，第二届审计委员会第十次会议，审议通 过了《关于使用部分暂时闲置募集资金进行现金管理的议案》，同意董事会授权 董事长在上述额度范围内行使投资决策权并签署相关合同文件，公司财务总监 负责组织实施，公司财务管理部具体操作落实。 特别风险提示 公司使用最高额度不超过 2 亿元人民币暂时闲置募集资金进行现金管理， 为提高闲置募 ...

关于上海毕得医药科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上海毕 得医药科技股份有限公司（以下简称"毕得医药"、"公司"或"发行人"）首次公开 发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券交 易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法律法规和规范 性文件的要求，就毕得医药使用部分暂时闲置募集资金进行现金管理的事项进行 了审慎核查，并发表如下核查意见： 一、募集资金基本情况 国泰海通证券股份有限公司 | | | 1 | 1 | 药物分子砌块区域中心项目 | 28,000.00 | 28,000.00 | | --- | --- | --- | --- | | 2 | 研发实验室项目 | 7,435.61 | 7,435.61 | | 3 | 补充流动资金 | 8,000.00 | 8,000.00 | | | 合计 | 43,435.61 | 43,435.61 | 由于募投项目建设需要一定的周期，根据募投 ...

国泰海通证券股份有限公司 关于上海毕得医药科技股份有限公司 开展外汇套期保值业务的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或者"保荐机构"）作为上 海毕得医药科技股份有限公司（以下简称"公司"、"毕得医药"）首次公开发行股 票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海 证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》等有关法律法规和规范性文件的要求，对公司计划开展 外汇套期保值业务的事项进行了核查，具体情况如下： （二）资金来源 1 资金来源为自有资金，不涉及募集资金。 二、拟开展的外汇套期保值业务概述 （一）交易金额 公司及控股子公司拟开展的外汇套期保值业务资金额度为：任一交易日持有 的最高合约价值不超过 6 亿元人民币或其他等值货币，预计动用的交易保证金和 权力金任一交易日不超过 2,000 万元人民币或其他等值货币。开展期限内任一时 点的交易金额（含前述外汇套期保值业务的收益进行再交易的相关金额）不超过 前述额度范围。 一、开展外汇套期保值业务的背景及目的 公司及控股子公司进出口业务主要采用美元等外币进行结算，因 ...

证券代码：688073 证券简称：毕得医药 公告编号：2025-082 上海毕得医药科技股份有限公司 关于计划开展外汇套期保值业务的公告 交易主要情况 已履行及拟履行的审议程序 2025 年 10 月 15 日，上海毕得医药科技股份有限公司（以下简称"公 司"）召开了第二届董事会第二十五次会议，第二届审计委员会第十次会议， 审议通过了《关于计划开展外汇套期保值业务的议案》。本议案无需提交公 司股东会审议。 特别风险提示 公司的套期保值业务以正常生产经营为基础，以规避和防范汇率风险 为目的，不进行单纯以盈利为目的的投机交易。但外汇套期保值业务操作 仍存在一定的汇率波动风险、法律风险等，敬请投资者注意投资风险。 一、交易情况概述 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 交易目的 | □获取投资收益 ☑套期保值（合约类别：□商品；☑外汇；□其他：________） | | --- | --- | | | □其他：________ | | 交易品种 | 即期结售汇、远期结售汇（定期、择期）、掉期及期权等外 ...

上海毕得医药科技股份有限公司 关于开展外汇套期保值业务的可行性分析报告 一、开展外汇套期保值业务的背景及必要性 随着上海毕得医药科技股份有限公司（以下简称"公司"）国际贸易业务规 模的不断扩大，公司相应的外币收付款、外币存贷款的金额不断增长，汇率波动 对公司经营成果的影响日益增大。为进一步提高公司应对外汇波动风险的能力， 更好地规避和防范汇率、利率波动的风险，增强公司财务稳健性，公司拟开展外 汇套期保值业务，加强公司外汇风险管理，有效降低外汇市场波动对公司经营产 生的负面影响，增强公司财务稳健性。因此外汇套期保值业务具有必要性。 二、开展外汇套期保值业务概述 （一）交易金额 公司及控股子公司拟开展的外汇套期保值业务资金额度为：任一交易日持有 的最高合约价值不超过6亿元人民币或其他等值货币，预计动用的交易保证金和 权力金任一交易日不超过2,000万元人民币或其他等值货币。开展期限内任一时 点的交易金额（含前述外汇套期保值业务的收益进行再交易的相关金额）不超过 前述额度范围。 （二）资金来源 资金来源为公司自有资金，不涉及募集资金。 （三）交易方式 公司及控股子公司拟开展的外汇套期保值业务运用银行即期结售汇、远期 ...

从资金流向上来看，当日医疗服务板块主力资金净流出10.66亿元，游资资金净流入2.9亿元，散户资金净 流入7.76亿元。医疗服务板块个股资金流向见下表： 证券之星消息，10月14日医疗服务板块较上一交易日下跌2.17%，毕得医药领跌。当日上证指数报收于 3865.23，下跌0.62%。深证成指报收于12895.11，下跌2.54%。医疗服务板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002173 | 创新医疗 | 21.95 | 1.95% | 54.61万 | 12.04亿 | | 688238 | 和元生物 | 7.80 | 1.30% | 21.44万 | 1.69亿 | | 603456 | 九州药业 | 19.55 | 1.30% | 37.11万 | 7.35亿 | | 300015 | 爰尔眼科 | 12.66 | 1.12% | 96.29万 | 12.20亿 | | 002622 | 皓宸医疗 | 3.18 | 0.63% | 53.79万 | 1.7 ...

Core Viewpoint - On October 10, Bid Pharma experienced a decline of 6.71% in stock price, with a trading volume of 64.09 million yuan, indicating market volatility and investor sentiment towards the company [1]. Financing Summary - On the same day, Bid Pharma had a financing purchase amount of 7.73 million yuan, with a net financing purchase of 4.02 million yuan after accounting for repayments [1]. - The total financing and securities balance for Bid Pharma reached 39.98 million yuan, which constitutes 1.28% of its market capitalization, indicating a low financing balance compared to the past year [1]. - In terms of securities lending, there were no shares sold or repaid on October 10, with the securities lending balance also at zero, suggesting a high level of investor confidence or lack of short-selling activity [1]. Company Profile - Shanghai Bid Pharma Technology Co., Ltd. was established on April 27, 2007, and went public on October 11, 2022. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [2]. - The main revenue components include: 43.26% from molecular building block heterocyclic compounds, 23.32% from aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [2]. - As of June 30, 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%, and a net profit attributable to shareholders of 73.41 million yuan, reflecting a 41.60% increase year-on-year [2]. Shareholder Information - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. - As of June 30, 2025, the company had 3,782 shareholders, an increase of 4.76% from the previous period, with an average of 11,431 circulating shares per shareholder, a decrease of 4.55% [2][3]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which holds 4.25 million shares, and Agricultural Bank of China Medical Health Stock, which increased its holdings by 177,500 shares [3].

Core Insights - On October 9, 2023, brokerage firms set target prices for listed companies, with notable increases for companies in the personal care, medical device, and semiconductor industries [1][2]. Group 1: Target Price Increases - The companies with the highest target price increases include: - Steady Medical (稳健医疗) with a target price increase of 44.29%, rated "Buy" by CITIC Securities, with a target price of 56.00 yuan [2]. - Sanor Bio (三诺生物) with a target price increase of 35.27%, rated "Recommended" by Huachuang Securities, with a target price of 27.00 yuan [2]. - Tongfu Microelectronics (通富微电) with a target price increase of 24.46%, rated "Buy" by Qunyi Securities (Hong Kong), with a target price of 55.00 yuan [2]. Group 2: Brokerage Recommendations - A total of 27 listed companies received brokerage recommendations on October 9, with BYD (比亚迪) receiving recommendations from two firms, while Qianhong Pharmaceutical (千红制药) and Mulinsen (木林森) each received one recommendation [2]. Group 3: Rating Adjustments - Northeast Securities upgraded Jiangfeng Electronics (江丰电子) from "Hold" to "Buy" on October 9 [3]. - Five companies received initial coverage ratings on the same day, including: - Dongfang Guoxin (东方国信) rated "Buy" by Xinda Securities [3]. - Sanyou Medical (三友医疗) rated "Recommended" by Ping An Securities [3]. - Yidian Tianxia (易点天下) rated "Buy" by Zhongyou Securities [3]. - Jiangfeng Electronics (江丰电子) rated "Buy" by Northeast Securities [3]. - Cambrian (寒武纪) rated "Buy" by Huaxin Securities [3].

Investment Rating - The report maintains a "Recommendation" rating for the company with a target price of 91 yuan [2][8]. Core Insights - The company's H1 2025 performance exceeded expectations, with revenue of 628 million yuan (+17.91%) and a net profit of 73 million yuan (+41.60%) [2][8]. - The international business revenue grew by 21.40% to 363 million yuan, accounting for 57.9% of total revenue, indicating a strong market outlook [8]. - The overall gross margin improved to 44.25% (+4.74 percentage points), driven by higher international revenue [8]. - The net profit margin increased to 11.70% (+1.96 percentage points), reflecting enhanced profitability [8]. - The company is expected to achieve net profits of 147 million yuan, 206 million yuan, and 274 million yuan for 2025, 2026, and 2027, respectively, with corresponding EPS of 1.62 yuan, 2.27 yuan, and 3.02 yuan [8]. Financial Performance Summary - For H1 2025, the company reported a revenue of 628 million yuan, with a significant increase in net profit to 73 million yuan [2][8]. - The Q2 2025 results showed a revenue of 331 million yuan (+22.68%) and a net profit of 43 million yuan (+65.78%) [2][8]. - The projected total revenue for 2025 is estimated at 1.331 billion yuan, with a year-on-year growth rate of 20.7% [4][8]. - The projected net profit for 2025 is 147 million yuan, reflecting a growth rate of 25.1% [4][8]. Business Segment Performance - The drug molecular building blocks generated revenue of 520 million yuan (+14.35%), accounting for 82.94% of total revenue [8]. - The scientific reagent business saw a remarkable growth of 38.95%, with revenue reaching 107 million yuan [8]. - The catalyst and ligand revenue was 66 million yuan (+19.87%), while life science reagents surged to 41 million yuan (+87.60%) [8].